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Abstract
Aim: Study the prevalence of metabolic syndrome (MS) and risk factors for and association with elevated alanine
aminotransferase (ALT) as markers of hepatic injury in a large Hispanic health disparity cohort with high rates of obesity.
Methods: Analysis of data from a prospective cross-sectional population based study. From 2004-7, we randomly recruited
2000 community participants to the Cameron County Hispanic Cohort collecting extensive socioeconomic, clinical and
laboratory data. We excluded 153 subjects due to critical missing data. Pearson chi-square tests and Student’s t-tests were
used for categorical and continuous variable analysis, respectively. Logistic regression analysis was performed to determine
the risk factors for elevated ALT.
Results: The mean age of the cohort was 45 years and 67% were females. The majority of the cohort was either overweight
(32.4%) or obese (50.7%). Almost half (43.7%) had MS and nearly one-third diabetes. Elevated ALT level was more prevalent
in males than females. Obesity was a strong risk for abnormal ALT in both genders. Hypertriglyceridemia,
hypercholesterolemia and young age were risks for elevated ALT in males only, whereas increased fasting plasma glucose
was associated with elevated ALT in females only.
Conclusion: We identified high prevalence of MS and markers of liver injury in this large Mexican American cohort with
gender differences in prevalence and risk factors, with younger males at greatest risk.
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Introduction
Minority populations including Hispanics suffer from severe
health consequences of many preventable diseases, prominently
obesity, diabetes and their complications. One of the complica-
tions of obesity is liver injury from nonalcoholic fatty liver disease
(NAFLD) [1]. We have been recruiting and studying a community
cohort of more than 2000 Mexican Americans living on the US/
Mexico border for several years (the Cameron County Hispanic
Cohort: CCHC) [2]. Among these health disparity participants,
we have found extremely high rates of obesity (52%) and diabetes
(20%). In an earlier chart review from a clinic serving the same,
largely uninsured population we documented high frequency of
chronic end-stage liver disease and hepatocellular carcinoma.
Using ICD9 discharge data codes for all forms of end-stage liver
disease, we found rates of 126/100,000 overall rising to136/
100,000 in males [3]. Anecdotally gastroenterologists in the region
reported that they see large number of patients with NAFLD, and
the more severe consequence; nonalcoholic steatohepatitis
(NASH). Accordingly we sought to obtain more precise prevalence
data and better understanding of underlying risk factors as a first
step to establishing burden of disease and developing interven-
tions.
Most of the published prevalence information on NAFLD was
derived from studies of Caucasian cohorts. According to a study
based on the Third National Health and Nutrition Examination
Survey (1988–1994), elevation of serum aminotransferases was
more common in Mexican Americans than non-Hispanic whites
[4]. The prevalence of NAFLD has been shown to be higher in
Hispanic population than other ethnicities [5–7]. However, the
number of Hispanics in these studies was relatively small, including
two population-based reports [5,6]. In addition, selection bias is a
risk in non-population-based studies.
Serum alanine aminotransferase (ALT) is frequently used as a
surrogate marker for liver injury. The upper limit of the normal
range varies in different laboratories according to the commercial
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normal values have historically been set at around 40 units per liter
(U/L) [8]. NAFLD is the commonest cause of abnormal liver
enzymes in the developed world [1]. It is estimated that 20–30% of
general population in Western countries and 18% in Japan have
NAFLD [9,10]. The prevalence of NAFLD further increases to
91% in morbidly obese patients undergoing bariatric surgery [11]
and 69.5% in patients with type 2 diabetes [12]. NAFLD is highly
associated with such features of the metabolic syndrome (MS) as
obesity, hypertension, dyslipidemia, and insulin resistance. It is
even being considered as the liver manifestation of MS [1]. Among
patients with NAFLD, 18% of normal-weight and 67% of obese
subjects have MS [13].
To achieve our objectives we used weighted data from the
CHCC cohort, to determine the prevalence of and risk factors for
elevated ALT in this large Hispanic cohort. We focus especially on
the known risks associated with MS.
Methods
Study population
From 2004 through 2007, we recruited 2000 participants to the
CCHC [2]. These individuals were randomly selected based on
the 2000 Census tract data in the city of Brownsville, Texas, one of
the poorest Hispanic regions in US. Over 90% of the participants
are Mexican Americans and over three quarters do not have
health insurance of any kind [2]. A written consent was obtained
from each participant. During the initial visit, participants were
asked to complete a comprehensive questionnaire regarding their
basic demographic information, medical history, medication use,
and social and family history as described previously [2]. Blood
samples were taken and aliquots immediately stored at 270uC for
a range of clinical and experimental assays. Blood glucose and
CBC were performed on site. Stored specimens were sent in
batches to a CLIA approved clinical laboratory for clinical
chemistries, including liver function tests. In our analyses we
defined elevated ALT equal to or greater than 40 U/L. MS is
defined based on the American Heart Association definition [14].
Briefly, MS is defined as the presence of at least three of the
following: elevated waist circumference, $102 cm or 40 inches for
men or $88 cm or 35 inches for women; elevated triglycer-
ides$150 mg/dl; reduced HDL cholesterol, ,40 mg/dl for men
or ,50 mg/dl for women; elevated blood pressure$130/85 mm
Hg or use of medication for hypertension; and elevated fasting
glucose$100 mg/dl or use of medication for hyperglycemia. For
assessment of Homeostasis Model Assessment Insulin Resistance
(HOMA-IR), we measured fasting serum insulin levels.
This study has been approved by the Institutional Review Board
of the University of Texas Health Science Center at Houston. We
analyzed the demographic and laboratory data from each
participant to determine the prevalence of and the risks associated
with ALT elevation. After excluding 153 subjects due to missing
liver enzyme or HOMA data, 1847 subjects were included in the
final analysis.
Statistical analysis
Data are presented as means6SD for continuous variables and
as frequencies for categorical variables. Comparisons between the
two groups (ALT,40 vs. ALT$40 U/L) were performed with
Pearson chi-square tests for categorical variables, and Student’s t-
tests for continuous variables. Univariate analysis with logistic
regression was performed in order to determine the predictors of
elevated ALT levels. Only those variables that had a statistically
significant effect at the 0.05 level in the univariate analyses
remained in the multivariate model. Unadjusted and adjusted
odds ratios and 95% confidence intervals were presented. All
reported p values were two-sided, and a p value of less than 0.05
was considered to indicate statistical significance. All statistical
analyses were performed with SPSS 15.0 (SPSS Inc, Chicago, IL).
Results
Descriptive characteristics of the study cohort
As shown in Table 1, the mean age of the cohort subset we
studied was 45 years. There were more females than males (67%
vs. 33%, respectively). Overall, 83.1% of the study subjects were
either overweight (32.4%) [body mass index (BMI) between 25 and
29.9] or obese (50.7%) (BMI$30). Nearly half (43.7%) have MS.
Almost one-third have diabetes (American Diabetes Association
2010 definition) [15].
The cohort was further divided into 2 groups based on serum
ALT levels as described. Elevated ALT level was more prevalent
in males than females (figure 1). In addition, subjects with elevated
ALT levels were younger (30–40 years), particular the males, were
more obese, and were more likely to have features of MS especially
Table 1. Descriptive characteristics of the study cohort based
on serum ALT levels.
Overall ALT,40 ALT$40 P
N=1847 N=1119 N=728
Age (yr) 45.0615.2 46.3616.2 43.2613.2 ,0.001
Gender
Female 1238 (67) 861 (76.9) 377 (51.8)
Male 609 (33) 258 (23.1) 351 (48.2) ,0.001
BMI
,25 312 (17) 235 (21.2) 77 (10.5)
25–29.9 595 (32.4) 387 (34.9) 208 (28.6)
$30 931 (50.7) 488 (44.0) 443 (60.9) ,0.001
ALT/AST ratio$1 1283 (69.5) 684 (61.1) 599 (82.3) ,0.001
Metabolic syndrome 801 (43.7) 442 (39.8) 359 (49.7) ,0.001
High blood pressure
" 432 (23.4) 249 (22.3) 183 (25.2) 0.15
Waist circumference
{ 1258 (68.2) 743 (66.6) 515 (70.7) 0.06
Serum triglyceride$150 mg/dL 795 (43.3) 423 (37.9) 372 (51.5) ,0.001
Plasma glucose$100 mg/dL 711 (38.5) 385 (34.4) 326 (44.8) ,0.001
Low serum HDL
£ 927 (50.4) 556 (49.8) 371 (51.2) 0.5
Total cholesterol$200 mg/dL 679 (36.8) 375 (33.6) 304 (42.0) ,0.001
Diabetes
* 508 (27.6) 292 (26.2) 216 (29.8) 0.09
Ever smoke 547 (29.6) 284 (25.4) 263 (36.1) ,0.001
Ever drink alcohol 912 (49.4) 490 (43.8) 422 (58.0) ,0.001
Fasting serum insulin (mU/mL) 15.7613.3 13.469.4 19.2617.2 ,0.001
HOMA 4.464.7 3.663.0 5.566.3 ,0.001
Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; HDL, high density lipoprotein; HOMA, homeostatic
model assessment.
Note: continuous variables are means6SD and categorical variables are
numbers (%).
"Systolic pressure$130 or diastolic pressure$85 mm Hg.
{$102 cm in males and $88 cm in females.
£,40 mg/dL in males and ,50 mg/dL in females.
*Either fasting plasma glucose$126 mg/dL or HbA1C$6.5 or already on
treatment for diabetes.
doi:10.1371/journal.pone.0021515.t001
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was no significant difference in the prevalence of hypertension and
low high-density lipoprotein (HDL) levels between the 2 groups.
There was a trend for larger waist circumferences and more
diabetes in the group with elevated ALT. More subjects who had
elevated ALT had ever smoked or drank alcohol. Fasting serum
insulin levels and HOMA values were higher in subjects with
elevated ALT. The overwhelming majority (82.3%) of the subjects
with elevated ALT had an ALT to aspartate aminotransferase
(AST) ratio equal to or greater than 1, a feature usually seen in
individuals with NAFLD [1] (table 1).
Gender differences among the study cohort
The prevalence of elevated ALT was higher in males than
females (table 2 and figure 1). We therefore further characterized
the gender differences. Age and the prevalence of diabetes were
similar between genders. The female subjects were more obese
and more likely to have MS. On the other hand, male subjects had
higher total cholesterol levels and were more likely to have history
of smoking and alcohol drinking than female subjects. When
looking at the components of MS, female subjects were more likely
to have central obesity and low HDL levels. Male subjects were
likely to have elevated blood pressure, increased fasting triglyceride
levels, and increased fasting glucose levels. There was no gender
difference in fasting serum insulin levels or HOMA values. ALT/
AST ratio equal to or greater than 1 was more prevalent in males
than female counterparts.
Because of the existence of so many gender differences, it would
not be reasonable to pool genders together for analysis. Overall,
male gender had a 3-fold risk of developing elevated ALT levels
compared to females. We therefore further dichotomized the
cohort into 2 groups based on gender. During univariate analysis,
obesity (BMI$30), increased waist circumference and hypertri-
glyceridemia were significantly associated with elevated ALT in
both genders. Aging [odds ratio (OR) 0.7, 95% confidence
intervals (CI) 0.7–0.8], overweight (BMI 25–29.9) (OR 1.7, 95%
CI 1.03–2.7) and hypercholesterolemia (OR 1.7, 95% CI 1.2–2.4)
were significantly associated with elevated ALT in males only. On
the other hand, the presence of MS (OR 1.9, 95% CI 1.5–2.4),
hyperglycemia (OR 1.9, 95% CI 1.4–2.4), low serum HDL level
(OR 1.4, 95% CI 1.1–1.8), and history of diabetes (OR 1.5, 95%
CI 1.2–2.0) were significantly associated with elevated ALT in
females only. Neither history of hypertension nor history of ever
smoking or drinking alcohol predicted elevated ALT in both
genders (table 3).
The results of multivariate analysis are shown in table 4. Aging
was associated with lowering of ALT levels, especially in males
(figure 1). Obesity was a strong risk for elevated ALT in both
genders. There was a gender difference regarding the risk factors
of abnormal ALT. Hypertriglyceridemia (OR 1.6, 95% CI 1.06–
2.3) and hypercholesterolemia (OR 1.7, 95% CI 1.2–2.4) were
again significant risk factors for males but not females. On the
other hand, fasting glucose level greater than 100 mg/dl (OR 1.6,
95% CI 1.2–2.1) was a strong risk for abnormal ALT in females
but not at all in males.
In this study, we found that younger males were especially at
risk of having elevated ALT levels (figure 1). To find out the
possible explanation, the male subjects were divided into three
subgroups based on their age (age ,35, N=165; age 35–55,
N=286; age$56, N=158). In multivariate analysis, obesity
(BMI$30; OR 7.0, 95% CI 2.4–20.2) was strongly associated
with elevated ALT in males younger than but not old than 35
years. In addition, hypercholesterolemia (total cholester-
ol$200 mg/dl; OR 11.7, 95% CI 2.5–54.7) was also significantly
associated with elevated in males younger than 35 years but not in
males aged between 35 and 55. Hypercholesterolemia, neverthe-
less, was moderately associated with elevated ALT in males older
than 56 years (OR 2.7, 95% CI 1.3–5.6).
Figure 1. The association between age and ALT levels based on gender. The number of subject with serum ALT$40 U/L versus total subject
number in different age groups based on gender is displayed.
doi:10.1371/journal.pone.0021515.g001
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Using data from a well-characterized cohort of highly obese
Mexican Americans studied prospectively we have found alarmingly
high rates of both metabolic syndromeand raisedALT,suggestive of
widespread liver injury in this population. Furthermore our data
show that those with raised ALT are overwhelmingly likely to have
ALT:AST ratios greater than 1; suggestive of NAFLD [1]. Of great
concern was to find that younger males appeared to be the most
affected. Together these data show that Mexican Americans have a
high risk of developing NASH and end-stage liver disease, consistent
with our previous observations [3], and that this may now reach
epidemic proportions as the younger males in this population age.
We have previously reported gender differences in this cohort in
obesity and predictors of diabetes and cardiovascular disease,
particularly in younger men [16]. In this study, we found that
young males are especially at risk of having elevated ALT levels.
They are therefore at risk of developing complications of NAFLD
such as end-stage liver disease; another expensive complication of
modifiable conditions, such as obesity.
To our knowledge, this is the largest cross-sectional population-
based report focusing on the prevalence of and risk factors for
abnormal liver enzymes in Hispanics, specifically Mexican
Americans. Since the data were weighted, estimates of prevalence
of obesity and diabetes can be obtained, and overall these are very
high. Both are well known to be associated with NAFLD, which is
also the commonest cause of unexplained abnormal liver enzymes.
We therefore focus on the association of elevated ALT and MS
and its components during our analysis. We identified several
findings worthy of discussion.
We used ALT level equal to or greater than 40 U/L as the
normal cutoff value in this study. This value was historically based
on population studies conducted before the availability of blood
tests for hepatitis C and before the recognition of NAFLD [8]. The
upper limit of the normal (ULN) range of ALT varies in different
laboratories according to the commercial kit used and the
reference population chosen. Age, gender, and BMI may be
considered when determining the ULN for ALT [17,18]. A new
ALT ULN for healthy males and females was proposed to be
30 U/L and 19 U/L, respectively [19]. It is conceivable that more
people, especially women, with liver diseases may not be captured
by using higher ALT levels as normal cutoffs. Nevertheless, Kunde
and colleagues [20] reported that the new ALT standard proposed
by Prati and colleagues [19] may be helpful for early recognition of
the milder spectrums of NAFLD but may result in significant
healthcare expenditure and questionable benefit. When applying
the normal cutoffs proposed by Prati et al. [19] to the cohort of this
study, we found that the majority of the participants would have
abnormal ALT levels. Only 7 of 1238 female participants and only
68 of 609 male participants had ALT levels less than 19 U/L and
30 U/L, respectively. The findings argue that the normal ALT
cutoffs for Hispanics may be different than that proposed for other
ethnic populations [19].
The gender difference for the prevalence of elevated ALT in this
study was remarkable. Male subjects had a 3-fold risk of having
ALT level greater than 40 U/L compared to females. Similar
gender differences have been reported in 2 studies from Japan
[10,21] and another 2 US studies with mixed ethnicity [6,7]. One
of the 2 US studies [6] found sex differences in NAFLD especially
among Asians but they did not find significant gender-related
differences in BMI among Asians. The authors proposed that sex
differences in fat distribution may vary by race and ethnicity.
Males are prone to accumulate visceral fat regardless of total body
fat and deep subcutaneous adipose tissue has been associated with
insulin resistance in men but not in women [21,22]. Unlike the
studies mentioned previously, an Italian study [9] using a large
cohort reported gender is not a risk factor for NAFLD. However,
the authors further suggested that this conclusion applies to
Caucasians and might not be valid for other ethnicities.
We found that ALT levels decreased with age in both genders in
this study, similar to the findings observed in other studies [4,8,9].
The mechanism for this is unclear but both a cohort effect and/or
premature mortality in individuals with raised ALT at a young age
need to be considered. Dong and colleagues [8] reported that ALT
levels decline with age independent of MS components, adiposity
signaling biomarkers, and other commonly used liver function
tests. They proposed further studies are needed to establish the
optimal cutoff of normal ALT in the elderly.
Finally, we found that there were gender differences in the risk
factors for elevated ALT. Both obesity and hypertriglyceridemia
were associated with high ALT levels in both genders. High fasting
glucose in females and high cholesterol levels in males were
associated with high ALT levels. The explanation for these
disparities is currently unknown. Nonetheless, this interesting
finding suggests that each component of MS may have different
weight in relationship with abnormal liver enzymes in each
Table 2. Gender differences among the study cohort.
Female Male P
N=1238 N=609
Age (yr) 45.2614.9 44.8615.7 0.6
ALT
,40 861 (69.5) 258 (42.4)
$40 377 (30.5) 351 (57.6) ,0.001
BMI
,25 211 (17.1) 101 (16.8)
25–29.9 369 (29.9) 226 (37.5)
$30 656 (53.1) 275 (45.7) 0.003
Metabolic syndrome 567 (46.1) 234 (38.8) 0.003
High blood pressure
" 267 (21.6) 165 (27.1) 0.008
Waist circumference
{ 955 (77.2) 303 (49.9) ,0.001
Serum triglyceride$150 mg/dL 478 (38.8) 317 (52.4) ,0.001
Plasma glucose$100 mg/dL 450 (36.3) 261 (42.9) 0.007
Low serum HDL
£ 702 (56.9) 225 (37.1) ,0.001
Total cholesterol$200 mg/dL 431 (34.9) 248 (40.9) 0.01
Diabetes
* 344 (27.9) 164 (27.0) 0.7
HOMA 4.263.9 4.665.9 0.1
Fasting serum insulin (mU/mL) 15.3610.9 16.4617.2 0.1
Ever smoke 220 (17.8) 327 (53.8) ,0.001
Ever drink alcohol 433 (35) 479 (78.7) ,0.001
ALT/AST ratio$1 828 (66.9) 455 (74.7) 0.001
Abbreviations: BMI, body mass index; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; HDL, high density lipoprotein; HOMA, homeostatic
model assessment.
Note: continuous variables are means6SD and categorical variables are
numbers (%).
"Systolic pressure$130 or diastolic pressure$85 mm Hg.
{$102 cm in males and$88 cm in females.
£,40 mg/dL in males and ,50 mg/dL in females.
*Either fasting plasma glucose$126 mg/dL or HbA1C$6.5 or already on
treatment for diabetes.
doi:10.1371/journal.pone.0021515.t002
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mechanism.
A major limitation of this study is that it was not specifically
designed to study NAFLD, the diagnosis of which requires ruling
out other liver diseases first. Nevertheless, the numbers are large
and the data are impressive. This population-based study therefore
provides an unbiased snap shot of the prevalence of and risks for
abnormal liver tests in a large Hispanic cohort. Based on the
National Health and Nutrition Examination Survey (NHANES),
the prevalence rate of chronic hepatitis B and C infection in
Mexican Americans was only 0.07% and 2.6%, respectively
[23,24]. We previously had an opportunity to screen healthy
Hispanic volunteers who lived in Brownsville Texas for hepatitis B
and C as pre-employment physicals previously. Among 320
people, none had hepatitis C and only one had hepatitis B
infection (unpublished data). We therefore suspect the prevalence
of viral hepatitis is likely low in our cohort. Another limitation is
lack of detailed data regarding more than monthly alcohol
consumption among the subjects. Such information was provided
by the subjects voluntarily. However, the original questionnaire
was not designed to scrutinize such data in finer detail. We cannot
therefore exclude surreptitious alcohol use or other inaccuracies in
reporting.
In conclusion, our report highlights a previously undocumented
risk of end-stage liver disease in a health disparity population with
significant gender differences. The excess representation among
younger males is of particular concern. In this study, obesity
(BMI$30) and hypercholesterolemia (total cholesterol$200 mg/
Table 3. Univariate analysis of risk factors predicting elevated ALT based on gender.
Female Male
N=1238 N=609
OR (95% CI) P OR (95% CI) P
Age (by 10 yr increment) 1.0 (0.9–1.04) 0.3 0.7 (0.7–0.8) 0.001
BMI
25–29.9 1.5 (1.0–2.4) 0.6 1.7 (1.03–2.7) 0.04
$30 3.2 (2.2–4.8) ,0.0001 3.0 (1.9–4.8) ,0.0001
Metabolic syndrome 1.9 (1.5–2.4) ,0.0001 1.4 (0.97–1.9) 0.07
High blood pressure
" 1.2 (0.9–1.7) 0.1 0.9 (0.6–1.3) 0.6
Waist circumference
{ 2.2 (1.6–3.0) ,0.0001 1.6 (1.1–2.2) 0.006
Serum triglyceride$150 mg/dL 1.5 (1.2–1.9) 0.002 1.7 (1.3–2.4) 0.0009
Plasma glucose$100 mg/dL 1.9 (1.4–2.4) ,0.0001 1.0 (0.7–1.4) 0.9
Low serum HDL
£ 1.4 (1.1–1.8) 0.005 1.2 (0.8–1.7) 0.3
Total cholesterol$200 mg/dL 1.2 (0.9–1.6) 0.2 1.7 (1.2–2.4) 0.001
Diabetes
* 1.5 (1.2–2.0) 0.002 0.8 (0.6–1.2) 0.3
Ever smoke 1.3 (0.97–1.8) 0.08 0.9 (0.7–1.3) 0.5
Ever drink alcohol 1.2 (0.9–1.5) 0.2 1.2 (0.8–1.7) 0.4
Abbreviations: ALT, alanine aminotransferase; OR, odds ratio; CI, confidence interval; BMI, body mass index; HDL, high density lipoprotein.
"Systolic pressure$130 or diastolic pressure$85 mm Hg.
{$102 cm in males and$88 cm in females.
£,40 mg/dL in males and ,50 mg/dL in females.
*Either fasting plasma glucose$126 mg/dL or HbA1C$6.5 or already on treatment for diabetes.
doi:10.1371/journal.pone.0021515.t003
Table 4. Multivariate analysis of risk factors predicting elevated ALT based on gender.
Female Male
N=1238 N=609
OR (95% CI) P OR (95% CI) P
Age (by 10 yr increment) 0.8 (0.8–0.9) 0.0004 0.7 (0.6–0.8) ,0.0001
BMI
25–29.9 1.5 (0.97–2.5) 0.07 1.7 (0.99–2.8) 0.05
$30 2.9 (1.9–4.5) ,0.0001 2.7 (1.6–4.5) 0.0002
Serum triglyceride$150 mg/dL 1.3 (0.98–1.7) 0.07 1.6 (1.06–2.3) 0.02
Plasma glucose$100 mg/dL 1.6 (1.2–2.1) 0.0007 1.1 (0.8–1.6) 0.6
Total cholesterol$200 mg/dL 1.2 (0.91–1.6) 0.08 1.7 (1.2–2.4) 0.006
Abbreviations: ALT, alanine aminotransferase; OR, odds ratio; CI, confidence interval; BMI, body mass index.
doi:10.1371/journal.pone.0021515.t004
Prevalence and Risks of Abnormal ALT in Hispanics
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21515dl) were identified to be significantly associated with abnormal
ALT especially in younger males (age ,35 years). Studies are
needed to better define the risks, particularly better diagnostic
criteria allowing differentiation of NAFLD, and most importantly
NASH. This serious and potentially preventable public health
issue has major implications for health and wellbeing in this health
disparity population. Failing to intervene with preventive measures
will have considerable impact on the community and the economy
and will impact costs and capacity within the already stretched
health care system.
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